Multiple sclerosis: Could Roche’s bestselling drug Ocrevus be doing more harm than good in women with primary progressive MS?
Posted:
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of ocrelizumab for the treatment of primary progressive multiple sclerosis (PPMS) after allegations that the drug was approved despite internal concerns about its efficacy in women and a potential increased risk of breast cancer.
Leaders from across the NHS, government, industry and academia have called for a fundamental shift in how artificial intelligence is adopted across the health service, arguing that the NHS must move beyond isolated pilots and create clearer, faster routes to…
Health Innovation Kent Surrey Sussex (KSS) and Doctors Training have co-designed and co-delivered Generative AI (GenAI) training for NHS clinical staff, ensuring ethical, scalable, and high-quality workforce education.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us